JUBBONTI®
(denosumab)
SANDOZ
HK Reg. No. HK-68756 (15 Jul, 2025)
Composition:3
• Each pre-filled syringe contains 60 mg of denosumab in 1 mL of solution (60 mg/mL)
• This medicinal product contains 47 mg sorbitol in each mL of solution
Indication:3
• Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women denosumab significantly reduces the risk of vertebral, non-vertebral and hip fractures
• Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. In men with prostate cancer receiving hormone ablation, denosumab significantly reduces the risk of vertebral fractures
• Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture
References
3. EMA. JUBBONTI Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/jubbonti-epar-product-information_en.pdf. [Accessed 18 July 2025].
